CRIS Current Research Information System

TACCHETTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.750
NA - Nord America 6.340
EU - Europa 4.287
AF - Africa 430
SA - Sud America 345
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.163
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.264
VN - Vietnam 2.108
CN - Cina 1.726
SG - Singapore 1.621
IT - Italia 929
GB - Regno Unito 871
SE - Svezia 524
DE - Germania 520
HK - Hong Kong 380
FR - Francia 288
IN - India 280
BR - Brasile 236
NL - Olanda 213
RU - Federazione Russa 200
KR - Corea 184
IE - Irlanda 164
CI - Costa d'Avorio 147
UA - Ucraina 131
FI - Finlandia 124
ZA - Sudafrica 97
JP - Giappone 92
TG - Togo 79
SC - Seychelles 62
EE - Estonia 60
PH - Filippine 52
AR - Argentina 47
BG - Bulgaria 47
CH - Svizzera 46
BD - Bangladesh 45
CA - Canada 41
TH - Thailandia 37
BE - Belgio 36
JO - Giordania 34
AT - Austria 32
PL - Polonia 29
MX - Messico 28
TR - Turchia 24
ES - Italia 23
TW - Taiwan 23
ID - Indonesia 19
EC - Ecuador 18
IQ - Iraq 18
IR - Iran 18
CO - Colombia 15
LB - Libano 14
NG - Nigeria 14
SA - Arabia Saudita 13
CL - Cile 12
CZ - Repubblica Ceca 11
IL - Israele 10
PK - Pakistan 10
UZ - Uzbekistan 10
AU - Australia 8
EG - Egitto 7
GR - Grecia 7
LT - Lituania 7
MY - Malesia 7
VE - Venezuela 6
DZ - Algeria 5
PT - Portogallo 5
PY - Paraguay 5
RO - Romania 5
KE - Kenya 4
MA - Marocco 4
NP - Nepal 4
TN - Tunisia 4
AZ - Azerbaigian 3
OM - Oman 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CY - Cipro 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GH - Ghana 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NO - Norvegia 2
PS - Palestinian Territory 2
RS - Serbia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
GE - Georgia 1
HU - Ungheria 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MT - Malta 1
NC - Nuova Caledonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
QA - Qatar 1
Totale 18.158
Salva come PNG Salva come JPEG
Città #
Singapore 1.121
Ashburn 793
Southend 715
Fairfield 586
Chandler 570
Ho Chi Minh City 474
Hanoi 425
Hefei 368
Hong Kong 361
San Jose 276
Woodbridge 276
Bologna 258
Seattle 257
Wilmington 241
Ann Arbor 223
Beijing 218
Cambridge 215
Houston 215
Dong Ket 178
Dallas 176
Princeton 170
Santa Clara 168
Seoul 163
Dublin 160
Abidjan 147
Boardman 125
Lauterbourg 107
New York 103
Los Angeles 100
Helsinki 94
Lomé 79
Tokyo 74
Haiphong 70
Nanjing 70
Jacksonville 69
Bremen 66
Westminster 66
Padova 62
Council Bluffs 57
Milan 54
Frankfurt am Main 53
Berlin 52
Da Nang 50
Jinan 49
Sofia 46
Hyderabad 45
Buffalo 44
Turin 44
Munich 43
San Diego 40
Shenyang 39
Guangzhou 37
Changsha 36
Bengaluru 35
Redondo Beach 35
Amman 34
Bern 34
Brussels 34
Saint Petersburg 34
Redwood City 33
São Paulo 33
Shanghai 31
Nanchang 29
Tianjin 29
Zhengzhou 29
Redmond 26
Amsterdam 25
Johannesburg 24
Chicago 23
London 23
Fabriano 22
Hebei 22
Rome 22
Can Tho 21
Florence 21
Ha Long 21
Falkenstein 20
Lappeenranta 20
Nuremberg 20
Biên Hòa 19
Jiaxing 19
Paris 19
Vienna 19
Hangzhou 18
Hải Dương 18
Quận Bình Thạnh 18
Thái Nguyên 18
Ninh Bình 17
Shenzhen 17
Washington 17
Orem 16
Atlanta 15
Dongguan 15
Mülheim 15
Norwalk 15
Toronto 15
Wuhan 15
Brooklyn 14
Warsaw 14
Abeokuta 13
Totale 11.574
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 338
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 265
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 250
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 246
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 232
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 227
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 221
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 220
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 218
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 211
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 210
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 206
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 204
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 204
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 197
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 194
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 194
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 193
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 192
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 192
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 192
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 189
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 189
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 182
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 181
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 181
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 180
Thalidomide maintenance in multiple myeloma: certainties and controversies. 180
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 175
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 174
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 174
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 172
Dermoscopy of cutaneous involvement by multiple myeloma 172
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 172
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 171
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 169
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 156
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 156
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 154
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 154
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 153
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 152
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 151
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 151
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 147
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 143
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 143
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 143
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 142
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 141
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 137
Role of consolidation therapy in transplant eligible multiple myeloma patients. 136
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 135
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 134
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 134
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 134
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 133
Imaging in multiple myeloma: How? When? 133
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 132
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 131
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 129
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. 128
Extramedullary metastatic plasmacytoma in a multiple myeloma patient 128
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 127
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 123
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 120
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 119
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 118
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 114
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 113
Multiple myeloma: disease response assessment 110
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 107
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 105
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 104
null 98
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 97
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 93
Proteasome inhibitors: Bortezomib in multiple myeloma 91
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 90
Totale 17.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021577 0 0 0 0 0 0 0 0 0 62 82 433
2021/20221.727 180 75 98 132 157 79 33 117 65 173 311 307
2022/20232.299 211 354 102 356 144 204 77 121 358 78 174 120
2023/2024761 45 114 49 59 69 187 35 94 9 31 42 27
2024/20252.602 136 295 220 212 279 125 205 95 60 293 183 499
2025/20266.906 716 1.181 614 562 687 397 647 214 1.421 467 0 0
Totale 18.502